T cells generated from tumor-draining lymph nodes of patients with stage III melanoma were shown to mediate protective immune responses in vivo in a melanoma xenograft model, according to a report published in the Journal of Immunotherapy.
Not surprisingly, this was a very popular topic. I’m not sure why the ASCO planners didn’t anticipate this, because I had to wait a few minutes outside the door to even get in. At one point, it was standing room only!
MicroRNA (miRNA) profiling of samples from patients with metastatic melanoma who were treated with carboplatin/paclitaxel (CP) identified significantly higher expression of a specific microRNA (miR-659-3p) that was associated with longer progression-free survival (P = .008).
According to a retrospective analysis of four clinical trials, nivolumab (Opdivo) was deemed safe and effective in patients with wild-type or mutant BRAF gene mutation, regardless of prior BRAF inhibitor or ipilimumab (Yervoy) treatment.
Recently, I attended an event sponsored by Bristol-Myers Squibb featuring a medical oncologist who shared his experiences with nivolumab. An interesting observation he shared was that the side effects seem to be slightly different in patients with melanoma compared to those with NSCLC.
The US Food and Drug Administration's (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee (CTGTAC) and Oncologic Drugs Advisory Committee (ODAC) are giving the green light to a new cancer immunotherapy by Amgen Inc. known as T-Vec (talimogene laherparepvec/BLA 125518).
Adjuvant ipilimumab may significantly improve recurrence-free survival for patients with completely resected, high-risk stage III melanoma, according to a new randomized, double-blind phase III study published in The Lancet Oncology.